TIME FOR TRANSLATING PSYCHIATRIC GENETICS DISCOVERIES INTO CLINICAL APPLICATIONS

Recent discoveries in psychiatric genetics have yielded profound insights into the molecular underpinnings of neuropsychiatric disorders. While current efforts have successfully mapped the polygenic architecture of these conditions, existing knowledge relies heavily on case-control designs, which limits direct clinical translation. To achieve meaningful clinical impact, we must shift our focus toward understanding longitudinal dynamics, developmental trajectories, and patient outcomes. Although these recent discoveries offer promising translational pathways, accelerating progress requires a paradigm shift. This involves utilizing targeted discovery samples linked to specific clinical use cases, leveraging real-world data alongside federated analytical methodologies. Furthermore, integrating genetics with other data modalities will be essential. Leveraging birth cohorts and population-level data—empowered by artificial intelligence (AI) and longitudinal datasets—will play a pivotal role. Crucially, this transition demands closer collaboration with clinicians to define high-value use cases, operating within robust ethical frameworks and actively involving individuals with lived experience. Collectively, these advancements present unprecedented opportunities to accelerate the translation of psychiatric genetics into clinically useful applications.